

component; dermal or epidermal proliferation; bullosis or a collagen disorder; light-induced or chronological aging of the skin; actinic keratosis or pigmentation; chronological or actinic aging associated pathology; stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids; a cicatrization disorder; vibices; a sebaceous associated disorder; a viral related skin disorder; alopecia; a dermatological condition having an immunological component; and a skin disorder attributable to exposure to UV radiation; in a subject in need of said treatment, said method comprising administering to said subject, in an amount effective to treat said condition, a compound selected from the group consisting of 3-[3-(1-adamantyl)-4-methoxyphenyl]-3-methyl-2H-1-benzofuran-6-carboxylic acid, 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-6-carboxylic acid and 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-5-carboxylic acid.

57 (New). A method for the treatment of arteriosclerosis or hypertension in a subject in need of said treatment, said method comprising administering to said subject, in an amount which is therapeutically effective against arteriosclerosis or hypertension, a compound selected from the group consisting of 3-[3-(1-adamantyl)-4-methoxyphenyl]-3-methyl-2H-1-benzofuran-6-carboxylic acid, 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-6-carboxylic acid and 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-5-carboxylic acid.

58 (New). A method for the treatment of insulin-dependent diabetes in a subject in need of said treatment, said method comprising administering to said subject, in an amount which is therapeutically effective against insulin-dependent diabetes, a compound selected from the group consisting of 3-[3-(1-adamantyl)-4-methoxyphenyl]-3-methyl-2H-1-benzofuran-6-carboxylic acid, 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-6-carboxylic acid and 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-5-carboxylic acid.

59 (New). A method for the treatment of an ophthalmological disorder in a subject in need of said treatment, said method comprising administering to said subject, in an amount which is therapeutically effective against said ophthalmological disorder, a compound selected from the group consisting of 3-[3-(1-adamantyl)-4-methoxyphenyl]-3-methyl-2H-1-benzofuran-6-carboxylic acid, 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-6-carboxylic acid and 3-methyl-3-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthyl)-2H-1-benzofuran-5-carboxylic acid.